FDA approves Lucamzi, a ranibizumab biosimilar to Lucentis, for three eye conditions

The Food and Drug Administration has approved a new biosimilar version of ranibizumab, the eye injection first sold as Lucentis. On 27 October 2026 the agency cleared Lucamzi, developed by Xbrane Biopharma, under biologics licence application 761187 [s1]. The approval letter states plainly that the product was approved "as biosimilar to US-Lucentis (ranibizumab)," and authorises the company to market it under the proprietary name Lucamzi [s3].

A biosimilar is not a generic. Because biologic drugs are large, complex proteins grown in living cells, a follow-on version cannot be an identical copy; instead the manufacturer must show there are no clinically meaningful differences from the reference product in safety, purity and potency. Lucamzi (ranibizumab-blrz) carries an initial US approval year of 2026 and is a vascular endothelial growth factor (VEGF) inhibitor — a class of drugs that curbs the abnormal, leaky blood-vessel growth behind several sight-threatening retinal conditions [s2].

What it is approved to treat

The label lists three indications. Lucamzi is indicated for neovascular (wet) age-related macular degeneration; for macular oedema following retinal vein occlusion; and for myopic choroidal neovascularisation [s2]. All three are conditions in which fragile new vessels or fluid damage the macula, the central part of the retina responsible for sharp vision.

That is a narrower set than the full range the originator ranibizumab has carried over the years. Readers should note what the Lucamzi label does and does not claim: these three indications are the approved uses, and a biosimilar's licence extends only to the indications the FDA has granted it [s2]. The approval does not by itself make the drug interchangeable at the pharmacy counter; interchangeability is a separate designation, and nothing in the approval letter assigns it here [s3].

How it is given

Lucamzi is supplied as a 10 mg/mL solution and administered by intravitreal injection — delivered directly into the vitreous of the eye by an ophthalmologist. For each of its indications the recommended dose is 0.5 mg (0.05 mL) [s2]. For wet AMD the label recommends a monthly injection, roughly every 28 days, while noting that less frequent regimens are options after an initial series, albeit "not as effective" [s2]. For macular oedema after retinal vein occlusion the schedule is monthly; for myopic choroidal neovascularisation the label describes an initial monthly course of up to three months [s2]. This is a treatment measured in repeated clinic visits, not a one-off.

Why another ranibizumab matters

The economics are the story. Anti-VEGF injections are among the highest-volume, highest-cost drugs in ophthalmology, given to large numbers of older patients over years. Each biosimilar that reaches the market adds a competitor to the reference product and to the biosimilars already approved before it, and that competition is the mechanism through which these therapies are expected to become cheaper for health systems and patients over time. A new entrant does not guarantee a lower price on its own, but it is the precondition for one.

For patients, the clinical bottom line of a biosimilar approval is continuity: the FDA's standard is that there are no clinically meaningful differences from the reference drug, so the treatment experience and the monitoring are expected to mirror those of ranibizumab as already used [s2]. Ranibizumab has one of the longest track records in the anti-VEGF class, which is part of why a biosimilar of it can be brought to market on an abbreviated evidence package rather than a full programme of fresh outcome trials: the reference drug's behaviour is already well characterised, and the biosimilar's job is to match it [s2][s3].

What to watch

The practical questions now are commercial and logistical: when Lucamzi actually launches, how it is priced against Lucentis and the other ranibizumab biosimilars already on the market, and whether payers and retina clinics add it to their formularies and ordering systems. None of that is settled by the approval itself, which clears the regulatory hurdle but not the ones that determine whether patients ever see the drug.

Red flags: after any intravitreal injection, sudden eye pain, marked redness, new floaters, light sensitivity or a drop in vision can signal infection or raised eye pressure and warrant urgent ophthalmic review. This article describes an FDA approval and is not medical advice. Decisions about anti-VEGF therapy and which product to use belong with the treating eye specialist.